BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Santos J, António N, Rocha M, Fortuna A. Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review. Br J Clin Pharmacol 2020;86:533-47. [PMID: 31631392 DOI: 10.1111/bcp.14127] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Capiau A, De Backer T, Grymonprez M, Lahousse L, Van Tongelen I, Mehuys E, Boussery K. Appropriateness of direct oral anticoagulant dosing in patients with atrial fibrillation according to the drug labelling and the EHRA Practical Guide. Int J Cardiol 2021;328:97-103. [PMID: 33279589 DOI: 10.1016/j.ijcard.2020.11.062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bhatia HS, Bailey J, Unlu O, Hoffman K, Kim RJ. Response to "Direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease". Pacing Clin Electrophysiol 2020;43:267. [PMID: 31913502 DOI: 10.1111/pace.13873] [Reference Citation Analysis]
3 de Vries TAC, Hemels MEW, Cools F, Crijns HJGM, Yperzeele L, Vanacker P, Blankoff I, Lancellotti P, Mairesse GH, de Veer A, Casado Arroyo R, Catez E, de Pauw M, Vanassche T, de Asmundis C, Kirchhof P, De Caterina R, de Groot JR; ETNA-AF-Europe principal investigators from Belgium and the Netherlands. Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study. Acta Cardiol 2021;76:431-9. [PMID: 33406996 DOI: 10.1080/00015385.2020.1746095] [Reference Citation Analysis]
4 Zhang XL, Zhang XW, Wang TY, Wang HW, Chen Z, Xu B, Xu W. Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis. Circ Cardiovasc Qual Outcomes 2021;14:e007971. [PMID: 34932377 DOI: 10.1161/CIRCOUTCOMES.121.007971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hawkins NM, Er L, Sandhu RK, Kaul P, McAlister FA, Levin A, Andrade JG. Validity of different dose reduction criteria for apixaban. Am Heart J 2021;238:12-5. [PMID: 33762178 DOI: 10.1016/j.ahj.2021.03.004] [Reference Citation Analysis]
6 Mashiko T, Fujimoto S, Suda S, Abe A, Iguchi Y, Yagita Y, Kanzawa T, Okubo S, Kenichi T, Yamazaki M, Nakajima N, Kondo K, Inoue T, Iwanaga T, Terasawa Y, Shibazaki K, Kimura K. Prior direct oral anticoagulant dosage and outcomes in patients with acute ischemic stroke and non-valvular atrial fibrillation: A sub-analysis of PASTA registry study. Journal of the Neurological Sciences 2022. [DOI: 10.1016/j.jns.2022.120163] [Reference Citation Analysis]
7 Howe K, Bourke S, Sansom L. The extent to which off-patent registered prescription medicines are used for off-label indications in Australia: A scoping review. PLoS One 2021;16:e0261022. [PMID: 34860857 DOI: 10.1371/journal.pone.0261022] [Reference Citation Analysis]
8 Zhang C, Pan MM, Wang N, Wang WW, Li Z, Gu ZC, Lin HW. Feasibility and usability of a mobile health tool on anticoagulation management for patients with atrial fibrillation: a pilot study. Eur J Clin Pharmacol 2021. [PMID: 34671819 DOI: 10.1007/s00228-021-03236-4] [Reference Citation Analysis]
9 Lafaie L, Célarier T, Monreal M, Mismetti P, Delavenne X, Bertoletti L. The impact of advanced age on anticoagulant therapy for acute venous thromboembolism. Expert Opin Drug Metab Toxicol 2022;18:27-37. [PMID: 35195483 DOI: 10.1080/17425255.2022.2045273] [Reference Citation Analysis]
10 Comans AL, Sennesael AL, Bihin B, Regnier M, Mullier F, de Saint-Hubert M. Inappropriate low dosing of direct oral anticoagulants in older patients with non-valvular atrial fibrillation: Impact on plasma drug levels. Thromb Res 2021;201:139-42. [PMID: 33713867 DOI: 10.1016/j.thromres.2021.02.034] [Reference Citation Analysis]
11 Boriani G, Imberti JF, Vitolo M. Anticoagulation to prevent ischaemic stroke in patients with atrial fibrillation: a complex scenario including underdiagnosis, undertreatment, or underdosing of oral anticoagulants. European Heart Journal - Quality of Care and Clinical Outcomes 2020;6:95-7. [DOI: 10.1093/ehjqcco/qcaa013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Mavri A, Vene N, Božič-Mijovski M, Miklič M, Söderblom L, Pohanka A, Malmström RE, Antovic J. Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation. Sci Rep 2021;11:13908. [PMID: 34230559 DOI: 10.1038/s41598-021-93372-9] [Reference Citation Analysis]
13 Liu X, Huang M, Ye C, Xiao X, Yan C. Effect of non-recommended doses versus recommended doses of direct oral anticoagulants in atrial fibrillation patients: A meta-analysis. Clin Cardiol 2021;44:472-80. [PMID: 33682184 DOI: 10.1002/clc.23586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Steffel J, Ruff CT, Yin O, Braunwald E, Park JG, Murphy SA, Connolly S, Antman EM, Giugliano RP. Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. J Am Coll Cardiol 2021;77:1197-207. [PMID: 33663737 DOI: 10.1016/j.jacc.2020.12.053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
15 Kubota K, Ooba N. Effectiveness and Safety of Reduced and Standard Daily Doses of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: A Cohort Study Using National Database Representing the Japanese Population. CLEP 2022;Volume 14:623-39. [DOI: 10.2147/clep.s358277] [Reference Citation Analysis]
16 Vaitsiakhovich T, Coleman CI, Kleinjung F, Vardar B, Schaefer B. Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: evidence from the real-world CALLIPER study. Curr Med Res Opin 2022;:1-31. [PMID: 35392744 DOI: 10.1080/03007995.2022.2061705] [Reference Citation Analysis]
17 Bo M, Corsini A, Brunetti E, Isaia G, Gibello M, Ferri N, Poli D, Marchionni N, De Ferrari GM. Off-label use of reduced dose direct oral factor Xa inhibitors in subjects with atrial fibrillation: a review of clinical evidence. Eur Heart J Cardiovasc Pharmacother 2021;7:334-45. [PMID: 32853346 DOI: 10.1093/ehjcvp/pvaa103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Raccah PharmD PhD BH, Erlichman Y, Pollak A, Matok I, Muszkat M. Prescribing Errors With Direct Oral Anticoagulants and Their Impact on the Risk of Bleeding in Patients With Atrial Fibrillation. J Cardiovasc Pharmacol Ther 2021;:10742484211019657. [PMID: 34060932 DOI: 10.1177/10742484211019657] [Reference Citation Analysis]
19 Leblanc K, Bell AD, Ezekowitz JA, Tan MK, Laflamme D, Goldin L, Habert J, Lin PJ, Saunders K, Ngui D, Ng AP, Desroches J, Goodman SG; for the OPTIMAL AF Investigators. Non‐vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) Programme. Int J Clin Pract 2020;74. [DOI: 10.1111/ijcp.13625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Gilyarevskiy SR. Off-Label Medicines Use: Complex Problem of Modern Clinical Practice. Racionalʹnaâ farmakoterapiâ v kardiologii 2020;16:324-34. [DOI: 10.20996/1819-6446-2020-04-14] [Reference Citation Analysis]
21 Santos J, António N, Rocha M, Fortuna A. Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review. Br J Clin Pharmacol 2020;86:533-47. [PMID: 31631392 DOI: 10.1111/bcp.14127] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
22 Fernández MS, Marín F, Rafols C, Arribas F, Barrios V, Cosín-Sales J, Sánchez MA; the EMIR Study Investigators:. Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study). J Comp Eff Res 2021;10:583-93. [PMID: 33787316 DOI: 10.2217/cer-2020-0286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
23 de Vries TA, Hirsh J, Bhagirath VC, Ginsberg JS, Pisters R, Hemels ME, de Groot JR, Eikelboom JW, Chan NC. Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study. TH Open 2022;06:e10-7. [DOI: 10.1055/s-0041-1740492] [Reference Citation Analysis]
24 de Vries TAC, Hemels MEW, Cools F, Crijns HJGM, Yperzeele L, Vanacker P, Blankoff I, Lancellotti P, Mairesse GH, de Veer A, Casado Arroyo R, Catez E, de Pauw M, Vanassche T, de Asmundis C, Kirchhof P, De Caterina R, de Groot JR; ETNA-AF-Europe principal investigators from Belgium and the Netherlands*. Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study. Neth Heart J 2021;29:158-67. [PMID: 33411231 DOI: 10.1007/s12471-020-01518-7] [Reference Citation Analysis]
25 Wu X, Hu L, Liu J, Gu Q. Off-Label Underdosing or Overdosing of Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis. Front Cardiovasc Med 2021;8:724301. [PMID: 34568462 DOI: 10.3389/fcvm.2021.724301] [Reference Citation Analysis]
26 de Vries TAC, Hirsh J, Xu K, Mallick I, Bhagirath VC, Eikelboom JW, Ginsberg JS, Kruger PC, Chan NC. Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?—A Systematic Review. Thromb Haemost 2020;120:1323-9. [DOI: 10.1055/s-0040-1713889] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
27 Wirbka L, Haefeli WE, Meid AD; ARMIN Study Group. Estimated Thresholds of Minimum Necessary Adherence for Effective Treatment with Direct Oral Anticoagulants - A Retrospective Cohort Study in Health Insurance Claims Data. Patient Prefer Adherence 2021;15:2209-20. [PMID: 34594102 DOI: 10.2147/PPA.S324315] [Reference Citation Analysis]
28 De Luca L, Rubboli A, Lettino M, Tubaro M, Leonardi S, Casella G, Valente S, Rossini R, Sciahbasi A, Natale E, Trambaiolo P, Navazio A, Cipriani M, Corda M, De Nardo A, Francese GM, Napoletano C, Tizzani E, Nardi F, Roncon L, Caldarola P, Riccio C, Gabrielli D, Oliva F, Massimo Gulizia M, Colivicchi F. ANMCO position paper on antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and/or acute coronary syndromes. Eur Heart J Suppl 2022;24:C254-71. [PMID: 35663586 DOI: 10.1093/eurheartj/suac020] [Reference Citation Analysis]